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The molecular pathogenesis of dermatoﬁbrosarcoma protuberans (DFSP) involves distinctive rearrangement of chromosomes 17
and 22 leading to formation of the COL1A1-PDGFB fusion gene. The knowledge of molecular events underlying development of
DFSP resulted in the implementation of targeted therapy with imatinib—a tyrosine kinase inhibitor (TKI), to the clinical practice.
The striking eﬃcacy of imatinib in advanced cases of DFSP has been demonstrated in a few clinical trials. Thus, imatinib is
currently considered the gold standard in the treatment of inoperable and/or metastatic and/or recurrent cases of DFSP. Therapy
withimatinibmaypotentiallyfacilitateresectionordecreasepossibledisﬁgurementrelatedtoradicalsurgicalprocedure.Following
partial response on imatinib signiﬁcant percentage of patients may be rendered free of the disease by surgery of the residual tumor.
1.Introduction
Dermatoﬁbrosarcoma protuberans (DFSP) is a rare cutane-
ous-originsarcomawithusuallyindolentgrowth(overyears)
and low metastatic potential. Regional/distant metastases
probability is less than 5% [1, 2]. Metastases develop
more commonly in DFSP-containing areas of high-grade
ﬁbrosarcoma—ﬁbrosarcomatous-DFSP (DFSP-FS) [3–6],
which is characterized by more aggressive course. If distant
metastases occur they are often restricted to lungs, and
less commonly to lymph nodes. The standard treatment
of the localized disease is radical, wide local excision. It is
recommended that margins of the surgical excision should
exceed 2-3cm [1, 7]. This procedure often requires applica-
tion of reconstructive techniques and may result in cosmetic
disﬁgurement or functional impairment. Unfortunately, the
microscopically inﬁltrating pattern of tumor growth might
lead to high rates of unexpected positive margins. Local
recurrences may occur late, and they have been reported
withintherangeof24–90%[1,3,8–14].Nevertheless,several
reports provided data demonstrating lower frequency of
recurrence rate [15–17]. Recurrent disease is more challeng-
ing surgically, due to tumor ﬁxation to deeper structures.
Microscopic inﬁltrations spreading from the tumor might
also lead to high probability of unexpected nonradical
resection. There is only limited experience with Mohs micro-
graphic surgery in the treatment of localized DFSP [18–20].
2.MolecularPathogenesis
DFSP is characterized by the presence of distinctive, recip-
rocal rearrangement of chromosomes 17 and 22 in the
form of translocation t(17;22)(q22;q13) or supernumerary
ring chromosomes containing material from chromosomal
regions 17q22 and 22q 13 [21–31]. The rearrangement leads
to the fusion of alpha chain type a (COL1A1) localized on
17q22 to the platelet-derived growth factor beta (PDGFB)
localized on 22q13 (Figure 1)[ 32].
The PDGFB gene product is a growth factor that serves
as a ligand for the transmembrane receptor kinase PDGFRB.
The formation of COL1A1-PDGFB fusion gene results in the
constitutional upregulation of PDGFB expression, leading2 Sarcoma
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Figure 1: Schematic presentation of the COL1A1/PDGFB fusion gene formation.
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Figure 2: PDGFB break-apart FISH in interphase nuclei from
DFSP. (a) Schematic localization of FISH probes; (b) PDGFB
rearrangement detected by FISH, evidenced by one copy (red
probe) of the telomeric PDGFB signal in tumor cells (courtesy of
Professor M. Debiec-Rychter).
to continuous autocrine activation of PDGF receptor B
(PDGFRB) and as a consequence to propagation of the
mitotic signal by formation of an autocrine and paracrine
loops [33–35]. Greco et al. [36, 37] provided evidence,
that transfection with COL1A1-PDGFB fusion gene could
transform NIH3T3 cells. Furthermore, it was shown that by
using suramin, a compound known to interfere with PDGF-
PDGFR ligand-receptor interaction, the COL1A1-PDGFB
transformed phenotype in NIH3T3 cells can be reversed
[36].
Interestingly the presence of the speciﬁc COL1A1-
PDGFB fusion transcript was also identiﬁed in giant cell
ﬁbroblastoma (GCF) that is a histologic variant of DFSP.
GCF primarily aﬀects children so it is also called the juvenile
form of DFSP [38–41]. In DFSP-FS increased copy numbers
of COL1A1-PDGFB fusion gene were observed suggesting a
possible oncogenic mechanism of the clonal evolution from
DFSP into DFSP-FS [42].
Although there is no need for molecular conﬁrma-
tion of the diagnosis in the majority of DFSP cases, the
detection of the chromosomal 17;22 rearrangements or the
COL1A1-PDGFB fusion is a valuable diagnostic tool for
diﬀerential diagnosis of atypical, metastatic DFSP or DFSP-
FS. Currently two main molecular techniques are used:
ﬂuorescenceinsituhybridization(FISH)ormultiplexreverse
transcription polymerase chain reaction (RT-PCR). FISH
canbeperformedoninterphasenucleifromcellsuspensions,
touch prints, or frozen or ﬁxed paraﬃn-embedded sections
most commonly using break-apart PDGFB or COL1A1-
PDGFB fusion approach (Figure 2). On the other hand, RT-
PCR requires RNA extracted from tumor fragments and
necessitates the simultaneous use of several COL1A1 primers
(multiplex approach) as the breakpoint can randomly occur
between exons 6 and 47 [43–45].
3.TargetedTherapy
Advances in the understanding of molecular mechanisms of
DFSP resulted in the implementation of targeted therapy
basedonPDGFRinhibitiontothetreatmentofthissarcoma.
Imatinib mesylate is a tyrosine kinase inhibitor rationally
developed and speciﬁcally directed against BCR/ABL, KIT,
FMS (receptor for Colony Stimulating Factor 1), ARG
(ABL-related gene), and PDGFR alpha and beta. It has
been also found to be the ﬁrst eﬀective systemic therapy
in DFSP. Imatinib competes with adenosine triphosphate
(ATP) molecule, blocking tyrosine kinase receptor ability for
autophosphorylation, which in return results in inhibition
of the aberrant signal transduction pathway and partial
restoration of proper intracellular signaling. The observation
that autocrine overproduction of PDGFB caused by gene
rearrangement is a key pathogenetic factor [33, 34]f o r c e d
the in vitro research, which showed inhibition of DFSP cells
growth in vitro after exposure to imatinib [36, 46]. TheSarcoma 3
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Figure 3: Images of advanced dermatoﬁbrosarcoma protuberans of the supraclavicular region before and after therapy with imatinib, and
after resection of residual disease. The patient is now 3 years free of disease.
further demonstration of the imatinib inhibitory eﬀect on
six diﬀerent DFSP cell lines both in vitro and in vivo [37]
has led to the investigation of this new therapeutic approach
in the clinic. Early case reports on small series of patients
suggested the usefulness of imatinib in metastatic and locally
advanced DFSP [47–52]. Next series of 10 patients with
locallyadvancedand/ormetastaticDFSPtreatedwithinIma-
tinib Target Exploration Consortium Study B2225 showed
responses in all patients, including complete responses in
ﬁve out of 10 of locally advanced cases and one partial
response lasting seven months in metastatic case [53]. As a
consequenceimatinib was registered as a therapy of choice in
advanced (inoperable and/or metastatic) DFSPs (Figure 3).
In a phase II trial [54] evaluating the activity of imatinib in
life-threatening malignancies expressing imatinib-sensitive
tyrosine kinases DFSP was the only one of ﬁve tumor types
in which a notable activity was shown including extensive
regression in 10/20 cases (50% partial remissions, 33,3%
complete remissions).
Combined analysis of prematurely closed, two phase
II, single arm, open-label trials on eﬃcacy of imatinib in
advanced DFSP (European Organisation for Research and
Treatment of Cancer no. 62027 and the Southwest Oncology
Group no. S0345) has demonstrated the clinical beneﬁt with
rate exceeding 70% and median time to progression of 1.7
years on 25 patients with advanced DFSP [55]. Although
there were some diﬀerences in both trials’ design, the
observed responses’ rates were similar. These results imply
that the imatinib dose of 400mg daily has similar eﬃcacy
to 800mg daily in this entity. Rutkowski et al. [56]h a v e
proved striking activity of imatinib mesylate in advanced
DFSP in the group of 15 patients treated with imatinib in
routineclinicalpracticeoutsideanytrial,withclinicalbeneﬁt
rate approaching 80% as well as median PFS and OS being
not reached. In Table 1 the eﬃcacy results of imatinib in
advanced DFSPs from pooled analysis of phase II trials [55]
and 15 patients treated outside clinical trials is presented
[56].
It has also been shown that DFSPs-FS with t(17;22) are
stillimatinibsensitivealthoughresponsesseemtolastshorter
[57] while DFSPs-FS lacking the speciﬁc aberration do not
Table 1:Thebestoverallresponses,progression,andsurvivalstatus
in combined phase II clinical trials [55] and in group of patients
treated outside clinical trials [56].
Group of 24
patients treated in
phase II trials [55]
Group of 15 patients
treated outside
clinical trials [56]
N (%)
Progression status
Progression-free 12 (50) 11 (73)
Progression 12 (50) 4 (27)
Survival status
Alive 18 (75) 12 (80)
Dead 6 (25) 3 (20)
Best overall response
Partial response 11 (45.9) 11 (73)
Stable disease 6 (25) 1 (7)
Progressive disease 4 (16.6) 3 (20)
Not evaluable 3 (12.5) 0
respond to the treatment [53]. Therefore the conﬁrmation
of the molecular target (COL1A1-PDGFB fusion) presence
seems to be obligatory in every case prior to the start of
imatinib therapy.
Complete, wide surgical excision is the standard treat-
ment in localized, resectable cases, and in advanced cases it
may result in cosmetic disﬁgurement or serious functional
impairment. Thus the neoadjuvant imatinib strategy leading
to tumor downstaging and decrease of excision morbidity
by tissue-sparing appears to be very attractive. K´ erob et al.
[58] presented report on 25 resectable DFSP (median
size: 4.5cm) treated in phase II trial with preoperative
imatinib at the dose of 600mg daily for two months. The
objective partial response according to RECIST was observed
in nine cases (36%). The median relative tumor volume
decrease was 20% (range: 12.5–100%). Available clinical
data indicate that some DFSP patients initially evaluated as4 Sarcoma
unresectable/metastatic or necessitating mutilating surgery
turned out to have resectable tumor after imatinib therapy.
This rational approach enabling achievement of complete
remission may be potentially curative, although longer
followup is needed. Further studies are required for elucidat-
ing whether preoperative imatinib therapy reduces the need
for wide surgical margins or whether imatinib has activity as
adjuvanttherapyincaseswithpositive marginsafterexcision
or in other high-risk patients.
Majority of patients treated with imatinib experienced
side eﬀects during treatment, but almost all are mild and
manageable. The most common were ﬂuid retention/edema,
anemia, fatigue, nausea, skin rash, thrombocytopenia, vom-
iting,neutropenia,anddiarrhea,andtheyaresimilartothose
observed in patients with gastrointestinal stromal tumor
(GIST).
There are still several questions regarding imatinib
mechanism of action, and possible resistance to this targeted
therapy in DFSP. There is also a need to identify novel
predictive molecular markers for patients’ outcome. It was
presumed that imatinib eﬀect resulted from inhibition of
PDGFR phosphorylation. Surprisingly, clinical activity of
imatinib in DFSP is striking even in DFSP expressing
relatively low amounts of activated receptor. It seems that
inhibition of low-level receptor tyrosine kinase may be
eﬀective clinically if tumor cells are dependent on that
signaling mechanism, what has been observed also in pig-
mented villonodular synovitis/tenosynovial giant-cell tumor
[59, 60]. The better understanding of the downstream eﬀects
caused by imatinib-PDGFB interaction would allow deﬁning
additional treatment strategies for DFSP patients. In case
of disease progression after initial response to imatinib
the investigation of other multitargeted tyrosine kinase
inhibitors seems to be justiﬁed.
To summarize, imatinib therapy is currently the gold
standard in the treatment of inoperable and/or metastatic
and/or recurrent cases of DFSP, and this targeted therapy
may potentially facilitate resection or decrease possible
disﬁgurement. Signiﬁcant percentage of patients may be
rendered free of disease by surgery of residual disease
following partial imatinib responses. Current therapy of
DFSP with t(17;22) translocation should be conducted
by multidisciplinary team, including oncological surgeon.
The use of imatinib mesylate as initial therapy should be
considered to decrease possible extent of surgery and related
morbidity.
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